Voices
Kamal Saini: Phase 2/3 Trial Results of ADCs in TNBC in the Second-Line and Beyond
Kamal Saini/LinkedIn

Kamal Saini: Phase 2/3 Trial Results of ADCs in TNBC in the Second-Line and Beyond

Kamal Saini, Global Head, Oncology Therapeutic Expertise at Fortrea, shared a post on LinkedIn:

“We analyzed phase 2/3 trial results of antibody-drug conjugates (ADC) in triple-negative breast cancer (TNBC) in the second-line and beyond.

Seven trials had mature data:

  • ASCENT, EVER-132-001, and NCT05113966 examined 3L+ sacituzumab govitecan (SG)
  • OptiTROP-Breast01 evaluated 3L+ sacituzumab tirumotecan (ST)
  • METRIC examined 2/ 3L glembatumumab vedotin (GV)
  • EV-202 assessed 2L+ enfortumab vedotin (EV) efficacy and DESTINY-Breast04 evaluated 2L+ trastuzumab deruxtecan(T-DXd).

Outcome details in Table below, from our ASCO 2025 Abstract (lead by Dr Pérez Granado). Incremental progress is being made, but we have miles to go.”

Kamal Saini: Phase 2/3 Trial Results of ADCs in TNBC in the Second-Line and Beyond

Title: Systematic review of 2L+ ADC strategies in triple-negative breast cancer (TNBC).

Authors: Judith Pérez-Granado, Kamal Saini, Luca Cantini, Shakti Ramkissoon, Heidi C. Ko, Laura Vidal Boixader, Isagani Chico, Bruno Larvol, and Mark Gramling

Read The Full Article.

Kamal Saini: Phase 2/3 Trial Results of ADCs in TNBC in the Second-Line and Beyond

Neratinib With or Without Trastuzumab Shows Activity in HER2-Mutant Metastatic TNBC
Kamal Saini: Phase 2/3 Trial Results of ADCs in TNBC in the Second-Line and Beyond

Breast Cancer Bruno Larvol cancer Heidi C. Ko Isagani Chico Judith Pérez-Granado Kamal Saini Laura Vidal Boixader Luca Cantini Mark Gramling OncoDaily Oncology Pérez Granado Shakti Ramkissoon TNBC